Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa

Tropical Medicine and International Health

Volumn 20, Issue 10, 2015, Pages 1337-1345

  Cox, Helen ^a   Ramma, Lebogang ^a   Wilkinson, Lynne ^b   Azevedo, Virginia ^c   Sinanovic, Edina ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c City of Cape Town   (South Africa)

Author keywords

Cost; Decentralisation; Multidrug resistant tuberculosis; Rifampicin resistant tuberculosis; South Africa; Treatment

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

COHORT ANALYSIS; DECENTRALIZATION; DISEASE TREATMENT; DRUG; HEALTH EXPENDITURE; HOSPITAL SECTOR; SPATIOTEMPORAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; COMMUNITY PROGRAM; DECENTRALIZATION; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; RIFAMPICIN RESISTANT TUBERCULOSIS; SOUTH AFRICA; THERAPY RESISTANCE; TREATMENT DURATION; TREATMENT OUTCOME; COST; ECONOMICS; HOSPITALIZATION; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PRIMARY HEALTH CARE; STATISTICS AND NUMERICAL DATA; TIME; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

KHAYELITSHA; SOUTH AFRICA; WESTERN CAPE;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INFANT; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RIFAMPIN; SOUTH AFRICA; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84941178356     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12544     Document Type: Article

References (24)

1. World Health Organization. Global Tuberculosis Report 2014. World Health Organization, Geneva, 2014. Contract No.: WHO/HTM/TB/2014.08.
2. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012: 30: 63-80.
3. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: 2011 Update. World Health Organization: Geneva, 2011.
4. Padayatchi N, Friedland G. Decentralised management of drug-resistant tuberculosis (MDR- and XDR-TB) in South Africa: an alternative model of care. Int J Tuberc Lung Dis 2008: 12: 978-980.
5. National Health Laboratory Service. GeneXpert MTB/RIF Progress Report, July 2014. 2014.
6. Schnippel K, Rosen S, Shearer K et al. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health 2013: 18: 109-116.
7. National Department of Health South Africa. Management of drug-resistant tuberculosis: policy guidelines. Department of Health, South Africa, 2011.
8. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One 2013: 8: e54587.
9. Strategic Development Information and GIS Department (SDI&GIS) CoCT. City of Cape Town - 2011 Census Suburb Khayelitsha. City of Cape Town: Cape Town, 2013.
10. Western Cape Department of Health. Western Cape antenatal HIV survey 2012, 2013.
11. Medecins Sans Frontieres. Khayelitsha 2001-2011, Activity Report: 10 years of HIV/TB care at primary health care level, 2011.
12. Cox HS, McDermid C, Azevedo V et al. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One 2010: 5: e13901.
13. Cox H, Hughes J, Daniels J et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis 2014: 18: 441-448.
14. Medecins Sans Frontieres. Scaling up diagnosis and treatment of drug-resistant tuberculosis in Khayelitsha, South Africa, 2011.
15. Statistics South Africa. Statistical Release P0141 Consumer Price Index February 2012. Pretoria, South Africa, 2012. (Available from: http://www.statssa.gov.za/publications/P0141/P0141February2012.pdf) [14 October 2014].
16. Statistics South Africa. Statistical Release P0141 Consumer Price Index February 2013 Pretoria, 2013. (Available from: http://www.statssa.gov.za/publications/P0141/P0141February2013.pdf) [14 October 2014].
17. Sinanovic E, Ramma L, Vassall A et al. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis 2015: 19: 172-178.
18. Cegielski JP, Dalton T, Yagui M et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014: 59: 1049-1063.
19. Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 2010: 14: 413-419.
20. Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012: 366: 2151-2160.
21. Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014: 371: 723-732.
22. Cox H, Daniels J, Muller O et al. Impact of decentralized care and the Xpert MTB/RIF test on rifampicin-resistant tuberculosis treatment initiation in Khayelitsha, South Africa. Open Forum Infect Dis 2015: 2 [4 February 2015].
23. Sirgel FA, Tait M, Warren RM et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist 2012: 18: 193-197.
24. Bloss E, Kuksa L, Holtz TH et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010: 14: 275-281.